Wall Street brokerages expect that Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) will report $15.41 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Roivant Sciences’ earnings. The highest sales estimate is $24.83 million and the lowest is $6.00 million. The company is expected to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Roivant Sciences will report full-year sales of $61.02 million for the current fiscal year, with estimates ranging from $51.10 million to $70.89 million. For the next year, analysts anticipate that the company will report sales of $52.16 million, with estimates ranging from $8.40 million to $134.25 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Roivant Sciences.
Roivant Sciences (NASDAQ:ROIV – Get Rating) last posted its quarterly earnings results on Monday, February 14th. The company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.18). The company had revenue of $24.34 million for the quarter, compared to the consensus estimate of $10.13 million.
NASDAQ:ROIV opened at $4.05 on Friday. The company has a fifty day moving average of $5.52 and a 200 day moving average of $7.69. Roivant Sciences has a 52 week low of $3.73 and a 52 week high of $16.76.
In other news, COO Eric Venker sold 19,336 shares of the company’s stock in a transaction dated Wednesday, March 30th. The shares were sold at an average price of $4.84, for a total value of $93,586.24. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Rakhi Kumar sold 7,281 shares of the company’s stock in a transaction dated Friday, March 25th. The stock was sold at an average price of $5.06, for a total transaction of $36,841.86. The disclosure for this sale can be found here. Over the last three months, insiders have sold 357,794 shares of company stock worth $1,848,008.
Large investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP purchased a new stake in shares of Roivant Sciences in the 4th quarter worth about $108,000. InterOcean Capital Group LLC purchased a new stake in shares of Roivant Sciences in the 4th quarter worth about $121,000. Virtus ETF Advisers LLC purchased a new stake in shares of Roivant Sciences in the 4th quarter worth about $198,000. Virtu Financial LLC purchased a new stake in shares of Roivant Sciences in the 4th quarter worth about $203,000. Finally, Exos Asset Management LLC purchased a new stake in shares of Roivant Sciences in the 4th quarter worth about $210,000. 16.63% of the stock is currently owned by hedge funds and other institutional investors.
Roivant Sciences Company Profile (Get Rating)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- Get a free copy of the StockNews.com research report on Roivant Sciences (ROIV)
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.